Drug
Dasatinib
Dasatinib: highest development phase Phase 2, developed by Bristol-Myers Squibb, Hikma, Otsuka. 7 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bristol-Myers Squibb, Hikma, Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| dasatinib NCT01395017 | Phase 2 | Pancreatic Cancer |
| Dasatinib NCT03625388 | Phase 2 | Chronic Myelogenous Leukemia |
| Dasatinib NCT00777036 | Phase 2 | Leukemia |
| Dasatinib NCT02297139 | Phase 2 | Multiple Indications Cancer |
| Dasatinib NCT00982488 | Phase 2 | Leukemia |
| dasatinib NCT01030718 | Phase 1/2 | Chronic Myelogenous Leukemia |
| Dasatinib NCT04115059 | Phase 1 | Waldenstrom Macroglobulinemia |
Latest
No recent events.
Follow Dasatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.